WHAT YOU NEED TO KNOW: CAPA Executive Director Matthew Lane Takes Part in R Street Patent Week Panel On June 6, CAPA Executive Director Matthew Lane took part in an R Street panel around Patent Quality Week. The conversation centered around current flaws in the U.S. patent system that enable abuses and results in high drug […]

Continue Reading

WHAT YOU NEED TO KNOW: DID YOU KNOW: Biosimilar Competition Could Reduce Costs for Patients and Drive Accessibility to Lifesaving MedicationsRecently, Inside Health Policy covered a new Cardinal Health report showing as many as 43 biosimilars slated to enter the market will lower U.S drug spending by $133 billion by 2024. Key excerpts: “Cardinal Health analysts predict […]

Continue Reading

WHAT YOU NEED TO KNOW: CAPA Dives Into What’s Driving Up Drug Prices: No-Innovation PatentingBrand name drug companies often attempt to bury competition from generic and biosimilar drugs indefinitely by finding ways to re-package existing inventions in later patents.  These later patents are often not innovative, meaning they are likely invalid.  A practice known as patent […]

Continue Reading

WHAT YOU NEED TO KNOW: IN CASE YOU MISSED IT: CAPA Executive Director Quoted In NYT Editorial Calling Out Patent Abuse & Highlighting Reforms to U.S. Patent System The New York Times recently published an editorial titled, “Save America’s Patent System” that focuses on measures lawmakers and regulators should take to reform the U.S. patent […]

Continue Reading

WHAT YOU NEED TO KNOW: ICYMI: Kathi Vidal Confirmed as Director of U.S. Patent and Trademark Office In case you missed it, the U.S. Senate confirmed Katherine Vidal as Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office (USPTO). To read the full statement, click here.  The Evidence […]

Continue Reading

WHAT YOU NEED TO KNOW: CAPA Joins Leading Organizations in Support of Patent Reform, Calls on Congress to Pass Legislation to Lower Drug CostsThe Coalition Against Patent Abuse (CAPA) along with fourteen organizations from across the political spectrum sent a letter to Senator Patrick Leahy (D-VT), Senator Dick Durbin (D-IL), Senator Chuck Grassley (R-IA) and Senator Thom […]

Continue Reading

WHAT YOU NEED TO KNOW: The Truth Behind Patent Thickets: Why Lawmakers Need to Tackle Big Pharma’s Patent Abuse that Prevents Lower-Cost Medicines from Entering the MarketplaceMany pharmaceutical companies engage in patent thicketing to bury competition from generic and biosimilar drugs by finding ways to re-patent existing inventions.  The process of patent thicketing is increasingly […]

Continue Reading

WHAT YOU NEED TO KNOW: Did You Know: The Inter Partes Review (IPR) Process is a Faster, Cost-Effective Tool to Correcting Low-Quality Patents? For over a decade, IPR has been among the most utilized tools in lowering drug prices and to date has saved over $2 billion in deadweight loss by reducing the cost of […]

Continue Reading

WHAT YOU NEED TO KNOW: Recent Study Points to Need for Patent Reform to Balance Competition with Innovation Recently, a new study by Nature Biotechnology revealed many pharmaceutical companies engage in patent thicketing to limit competition from lower-cost alternatives in the marketplace.  Out of the 21 patent lawsuits examined, only 6 percent of patents covered active […]

Continue Reading

WHAT YOU NEED TO KNOW: New Year, New Ways to Strengthen the U.S. Patent System For too long, some of the largest drug manufacturers have utilized low-quality patents to block market entry of affordable generic alternatives in order to extend exclusivity of their brand name drugs. To combat these anticompetitive tactics, reforms such as the America […]

Continue Reading